Bristol-Myers Squibb

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.This report presents a detailed study …

Profund Advisors LLC Sells 10,046 Shares of Bristol-Myers Squibb Co (NYSE:BMY) | 9/14/2019

Profund Advisors LLC cut its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.7% in the second quarter, HoldingsChannel reports. The firm owned 63,170 shares of the biopharmaceutical company’s stock after selling 10,046 shares during the period. Profund Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,865,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also …

Follow Bristol-Myers Squibb:    

Chilton Capital Management LLC Buys Shares of 12,646 Bristol-Myers Squibb Co (NYSE:BMY) | 9/14/2019

Chilton Capital Management LLC bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,646 shares of the biopharmaceutical company’s stock, valued at approximately $573,000. Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Bristol …

Bristol-Myers Squibb Co (NYSE:BMY) Shares Sold by Wesbanco Bank Inc. | Daily Political | 9/14/2019

Wesbanco Bank Inc. cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 409,471 shares of the biopharmaceutical company’s stock after selling 3,874 shares during the period. Bristol-Myers Squibb makes up about 0.9% of Wesbanco Bank Inc.’s portfolio, making the stock its 23rd largest holding. Wesbanco …

Wesbanco Bank Inc. Trims Position in Bristol-Myers Squibb Co (NYSE:BMY) | 9/14/2019

Wesbanco Bank Inc. Trims Position in Bristol-Myers Squibb Co (NYSE:BMY) Posted by Alphonse Anthony on Sep 14th, 2019 Tweet Wesbanco Bank Inc. trimmed its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 0.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 409,471 shares of the biopharmaceutical company’s stock after selling 3,874 shares during the period. Bristol-Myers Squibb accounts …

US Bancorp DE Purchases 16,620 Shares of Bristol-Myers Squibb Co (NYSE:BMY) | 9/14/2019

US Bancorp DE Purchases 16,620 Shares of Bristol-Myers Squibb Co (NYSE:BMY) Posted by Don Majors on Sep 14th, 2019 // Comments off US Bancorp DE lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,176,762 shares of the biopharmaceutical company’s stock …

Van Cleef Asset Management Inc Sells 300 Shares of Bristol-Myers Squibb Co (NYSE:BMY) | 9/14/2019

Van Cleef Asset Management Inc trimmed its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 15,090 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Van Cleef Asset Management Inc’s holdings in Bristol-Myers Squibb were worth $684,000 at the end of the most recent quarter. Other large investors also recently bought and sold …

MMRF Research Programs Drives New Breakthroughs in Multiple Myeloma Research | Business Wire | 9/13/2019

… profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF’s Personalized Medicine Initiative, the study is collecting and analyzing tissue samples, clinical data and genetic information from 1,000 newly diagnosed multiple myeloma patients for at least eight years. The CoMMpass Study was made possible by a $40M investment by the MMRF. The MMRF CoMMpass Study opened in …

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

… Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene (ticker: CELG), which is set to be acquired by Bristol-Myers (BMY), is getting for its blockbuster drug Otezla, and a “distinctly more positive catalyst path ahead.” He maintained his Overweight rating on Bristol stock …

Peptide Therapeutics Market – Growing Involvement of Pharmaceutical Companies to Trigger Market Growth | 9/13/2019

… other types of therapeutics are in the pre-clinical stage. A few of the prominent companies operating in the global peptide therapeutics market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Novo Nordisk A/S, and AstraZeneca PLC. Transparency Market Research (TMR) has prepared a report which predicts the market to expand at 9.10% CAGR during the assessment period of …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

SAN DIEGO, Sept. 13, 2019 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme’s ENHANZE® drug delivery technology in combination with intravenous …

Everett Harris & Co. CA Reduces Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY) | 9/13/2019

Everett Harris & Co. CA Reduces Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY) Posted by Rex Hubbard on Sep 12th, 2019 Tweet Everett Harris & Co. CA lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 10.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,450 shares of the biopharmaceutical company’s stock …

MML Investors Services LLC Purchases 10,346 Shares of Bristol-Myers Squibb Co (NYSE:BMY) | 9/13/2019

MML Investors Services LLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 7.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,816 shares of the biopharmaceutical company’s stock after purchasing an additional 10,346 shares during the quarter. MML Investors Services LLC’s holdings in Bristol-Myers Squibb were worth $6,885,000 as of its most …

Obermeyer Wood Investment Counsel Lllp Cuts Position in Bristol-Myers Squibb Co (NYSE:BMY) | 9/13/2019

Obermeyer Wood Investment Counsel Lllp lessened its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,600 shares of the biopharmaceutical company’s stock after selling 350 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Bristol-Myers Squibb were worth $707,000 as of its …

$1.06 Earnings Per Share Expected for Bristol-Myers Squibb Co (NYSE:BMY) This Quarter | 9/13/2019

Equities analysts expect that Bristol-Myers Squibb Co (NYSE:BMY) will report $1.06 earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Bristol-Myers Squibb’s earnings. The lowest EPS estimate is $1.03 and the highest is $1.09. Bristol-Myers Squibb posted earnings of $1.09 per share during the same quarter last year, which would indicate a negative year over year growth rate of …

Bristol-Myers Squibb Co (BMY) to Issue Quarterly Dividend of $0.41 on November 1st | 9/13/2019

… yield of 3.31%. Bristol-Myers Squibb has raised its dividend payment by an average of 2.6% annually over the last three years and has increased its dividend annually for the last 9 consecutive years. Bristol-Myers Squibb has a dividend payout ratio of 45.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Bristol-Myers Squibb to earn $5.36 per share next year, which means the company should …

Scotia Capital Inc. Acquires 84,596 Shares of Bristol-Myers Squibb Co (NYSE:BMY) - TheOlympiaReport | 9/13/2019

Scotia Capital Inc. increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 88.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 180,761 shares of the biopharmaceutical company’s stock after purchasing an additional 84,596 shares during the period. Scotia Capital Inc.’s holdings in Bristol-Myers Squibb were worth $8,198,000 as of its most recent …

Granite Investment Partners LLC Has $1.42 Million Holdings in Bristol-Myers Squibb Co (NYSE:BMY) | 9/13/2019

Granite Investment Partners LLC lessened its position in Bristol-Myers Squibb Co (NYSE:BMY) by 2.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,398 shares of the biopharmaceutical company’s stock after selling 915 shares during the period. Granite Investment Partners LLC’s holdings in Bristol-Myers Squibb were worth $1,424,000 at the end of the most recent …

Protocol Manager - Bristol-Myers Squibb - Eigenbrakel | 9/13/2019

Read what people are saying about working here. Braine-l’Alleud Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Join us and make a difference. We hire the best people and provide them with a work environment that places a …

Bristol-Myers Squibb Now #73 Largest Company, Surpassing Fidelity National Information Services | The Punxsutawney Spirit | 9/13/2019

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Bristol-Myers Squibb Co. (BMY) has taken over the 73 spot from Fidelity National Information Services Inc (FIS), according to The Online Investor …

Biotech

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

Bristol-Meyers Squibb Co. medication Photograph by Daniel Acker/Bloomberg Things are looking up for Bristol-Myers Squibb , according to one analyst at JPMorgan , even with the stock down 18.3% over the past 12 months. “Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene …

Prostate Cancer Therapeutics Market Development Plans, Size, Expected CAGR of 12.5%and Leading Industry Players: Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, etc | 9/9/2019

Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others. Download Free Sample Copy of [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market utm_source=NewsSB Succinct Description of the Market: Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to …

Food and Drug Administration

Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients | Business & Finance | manchestertimes.com | Business Wire | 9/10/2019

PRINCETON, N.J.–(BUSINESS WIRE)–Sep 10, 2019– Bristol-Myers Squibb Company (NYSE: BMY) today announced long-term pooled efficacy and safety results from the Phase 3 CheckMate -017 and CheckMate -057 studies in patients with … lead, Thoracic Cancers, Bristol-Myers Squibb, said, “Since the U.S. Food and Drug Administration approval in second-line non-small cell lung cancer in 2015, Opdivo has become an important treatment option for this population

CAR-TCR Summit Kickoff | 9/10/2019

Food and Drug Administration in 2017 for types of B-cell blood cancers. CAR-T treatments have been more successful with blood cancers and T-cell receptor therapies could be a key immunotherapy treatment for solid tumors – a much wider target for drugmakers. Companies in this space, such as Celgene, will certainly show off some of its latest data. Celgene, which is being acquired by Bristol-Myers Squibb, has a …

Big Pharma

Is Bristol-Myers Squibb a Buy? | The Motley Fool | 9/7/2019

Could the big pharma stock’s short-term pain turn into long-term gain for patient investors? Keith Speights ( TMFFishBiz ) Sep 7, 2019 at 12:30PM Bristol-Myers Squibb ( NYSE:BMY ) isn’t having a great year. The big pharma stock has spent most of 2019 in negative territory. Many investors weren’t happy with the decision to acquire Celgene ( NASDAQ:CELG ) . And BMS has experienced some clinical-study disappointments for its blockbuster cancer …

American Society of Clinical Oncology

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update | Globe Newswire | 8/14/2019

… cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Raised $13.8 million from a private placement … indications:• Melanoma - The UCLA School of Medicine, in collaboration with Bristol-Myers Squibb, is evaluating pepinemab in combination with the checkpoint inhibitors nivolumab and ipilumumab in two cohorts of patients with advanced melanoma whose tumors …

Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript - Nasdaq.com | 8/8/2019

… Phase 2 for EB study. Data from the COLUMBA study was the subject of an oral presentation at the 2019 American Society of Clinical Oncology annual meeting held in early June. The co-primary endpoints … products in Phase 1 development by our partners Argenx, Alexion, Bristol-Myers Squibb, Lilly and Roche. We were pleased to announce last month that Argenx had dealt with the first patient in a Phase 1 …

Medicare

5 Healthcare Stocks to Buy for Healthy Dividends | Yahoo News | 8/24/2019

… days, the healthcare stocks are looking pretty healthy compared to stocks in other spaces. Despite political pressures about lowering costs, “Medicare for All” and importing drugs, the sector has been riding high on a wave … payout has increased by 156% over the last 10 years. Bristol-Myers Squibb (BMY) Bristol-Myers Squibb (BMY) More Source: Shutterstock Dividend Yield: 3.43% The major pharmaceuticals are some of the best healthcare stocks to …

The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes | Yahoo News | 8/22/2019

… news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AngloGold Ashanti Ltd. AU, Bristol-Myers Squibb Co. BMY, Delta Air Lines, Inc. DAL, JD.com, Inc. JD and M … the federal government applies on wages to fund Social Security, Medicare, and other social insurance programs. But now, several Trump administration officials are considering a temporary payroll tax cut. A tax cut bodes well for …

ACA

The FDA Went on an Epic Drug Approval Binge This Week: Brainstorm Health | Fortune | 8/17/2019

… called “JAK inhibitor” approved for the bone marrow cancer myelofibrosis (and whose green light is a boon to drug giant Bristol-Myers Squibb , which is buying Celgene); and, finally, Rinvoq, a rheumatoid arthritis drug from … presidential candidates in the 2016 election. ( FiercePharma ) THE BIG PICTURE Obamacare replacement is a flat circle. Ok, I’m sorry for the now-dated pop culture reference . But here we are again. The Trump administration says …

The FDA Went on an Epic Drug Approval Binge This Week | Fortune | 8/17/2019

… called “JAK inhibitor” approved for the bone marrow cancer myelofibrosis (and whose green light is a boon to drug giant Bristol-Myers Squibb , which is buying Celgene); and, finally, Rinvoq, a rheumatoid arthritis drug from … presidential candidates in the 2016 election. ( FiercePharma ) THE BIG PICTURE Obamacare replacement is a flat circle. Ok, I’m sorry for the now-dated pop culture reference . But here we are again. The Trump administration says …

ACO

Star biotech analyst Mark Schoenebaum, loved for his humor as much as his work, dies | FierceBiotech | 8/26/2019

… Acorda CEO Ron Cohen in a tweet Monday morning. Cohen’s Twitter handle is a product of the “Best Hair in Biopharma” competition, created by Schoenebaum and run by BioSpace in 2014 and 2015. As the race continued, Schoenebaum wrote—in an investor note, no less—that “Bristol-Myers Squibb SVP of Public Affairs] John Elicker’s hair was simply incredible,” adding, “Sorry Ron Cohen, but you’ve got some serious competition. Who …

Retrophin Down on Neurological Disorder Drug Study Failure | Zacks | 8/23/2019

Bristol-Myers Squibb Company ( BMY - Free Report ) . Retrophin also has three commercial products — Chenodal, Cholbam and Thiola — in its portfolio. In June 2019, the FDA approved 100 mg and 300 mg tablets of Thiola EC (tiopronin), a new enteric-coated formulation of Thiola (tiopronin). Zacks Rank & Stock to Consider Retrophin currently carries a Zacks Rank 4 (Sell). A better-ranked stock in the biotech sector is Acorda Therapeutics ( ACOR - Free …

Department of Health and Human Services

White House Preparing Order That Would Cut Drug Prices for Medicare - Sources | Medscape | 7/26/2019

… declined to comment, and it was unclear how far along the any such plan was from being undertaken. The U.S. Department of Health and Human Services, also declined to comment. Americans pay the highest prices … Companies with major exposure to Part B include Merck & Co, Bristol-Myers Squibb Co and Roche. In early July, Trump said his administration was working on a drug pricing executive order with a “favored-nation …

Exclusive: White House preparing order that would cut drug prices for Medicare - sources | Yahoo News | 7/25/2019

… declined to comment, and it was unclear how far along the any such plan was from being undertaken. The U.S. Department of Health and Human Services, also declined to comment. Americans pay the highest prices … Companies with major exposure to Part B include Merck & Co, Bristol-Myers Squibb Co and Roche In early July, Trump said his administration was working on a drug pricing executive order with a “favored-nation …

Adverse Drug Reactions

Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | Business Wire | 6/24/2019

Weather AP Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma 17 min ago Save PRINCETON, N.J.–(BUSINESS WIRE)–Jun 24 … patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066

Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma - NASDAQ.com | 6/24/2019

PRINCETON, N.J.–(BUSINESS WIRE)– Company (NYSE: BMY ) today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo (nivolumab) versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). The trial did not achieve statistical significance for its primary endpoint of overall survival (OS) per the pre-specified analysis (HR=0.85 [95% CI: 0.72-1.02]; p=0.0752). No new safety signals were observed with …

NIH

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Core Grant P30 CA008748 (JEL, JHF, IJD and DHA) . This work was also supported by the National Institutes of Health (NIH) grant P30 EY010572 and by unrestricted departmental funding from Research to Prevent Blindness (AHS … Apexigen, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Eisai, personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted …

Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates | Globe Newswire | 8/8/2019

… May 2018, bringing 25 years of biopharmaceutical industry experience in CMC development and business operations to Corbus, most recently at Bristol-Myers Squibb. In his new role, Dr. Discordia will be responsible for optimizing the … being conducted and funded by the National Institutes of Health (NIH). SLE is a severe and sometimes life-threatening systemic autoimmune disease affecting approximately 550,000 people in the U.S., EU and Japan. Disease pathology can …

Celgene

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

Bristol-Meyers Squibb Co. medication Photograph by Daniel Acker/Bloomberg Things are looking up for Bristol-Myers Squibb , according to one analyst at JPMorgan , even with the stock down 18.3% over the past 12 months. “Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene

Bristol-Myers Squibb Board Announces Election of Three New Directors | Business Wire | 9/12/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected three new independent Directors: Michael Bonney, Dr. Julia A. Haller and Phyllis Yale will join the Board effective at the closing of the transaction with Celgene Corporation (NASDAQ: CELG). In connection with these elections, the size of the Board will increase at the time of the transaction close. Mr. Bonney and Dr. Haller …

Merck

Bristol-Myers Squibb Board Announces Election of Three New Directors | Business Wire | 9/12/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected three new independent Directors: Michael Bonney, Dr. Julia A. Haller and Phyllis Yale will join the Board effective … of Directors of Cubist Pharmaceuticals Inc. (which was acquired by Merck & Co., Inc. in January 2015) from June 2003 until December 2014. Prior to Cubist, he was Vice President, Sales and Marketing at Biogen, Inc

Global Neurology Market Research Overview 2019: Competitive Environment, Regulations, Epidemiology, M&As, Pipeline Drugs | PR Newswire | 9/12/2019

Bristol-Myers Squibb Co. Biogen Daiichi Sankyo Co., Ltd. Dr. Reddy’S Laboratories Ltd. Eli Lilly And Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ag Glaxosmithkline Plc Gedeon Richter Plc Immunocellular Therapeutics, Ltd. Johnson & Johnson Lannett Co., Inc. H. Lundbeck A/S Lupin Ltd. Mallinckrodt Merck & Co Mylan Nv Nextsource Biotechnology Llc Novartis Ag Otsuka Holdings Co., Ltd. Pfizer Inc. Sanofi Sumitomo Dainippon Pharma Co., Ltd. Sun Pharmaceutical Industries Ltd …

Pfizer

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges … Squibb, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis along with their product portfolio, market share, and other details. The major objective of this Bipolar Forceps and Microscissors Industry report is to

Peptide Therapeutics Market – Growing Involvement of Pharmaceutical Companies to Trigger Market Growth | 9/13/2019

Pfizer Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Novo Nordisk A/S, and AstraZeneca PLC. Transparency Market Research (TMR) has prepared a report which predicts the market to expand at 9.10% CAGR during the assessment period of 2016 – 2024. The research analysts at TMR prophesize that the global peptide therapeutics market is likely to acquire prominence reaching value of US$46.6 mn through 2024. Request a Sample of Peptide Therapeutics Market …

Novartis

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges … Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis along with their product portfolio, market share, and other details. The major objective of this Bipolar Forceps and Microscissors Industry report is to assist

Peptide Therapeutics Market – Growing Involvement of Pharmaceutical Companies to Trigger Market Growth | 9/13/2019

Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Novo Nordisk A/S, and AstraZeneca PLC. Transparency Market Research (TMR) has prepared a report which predicts the market to expand at 9.10% CAGR during the assessment period of 2016 – 2024. The research analysts at TMR prophesize that the global peptide therapeutics market is likely to acquire prominence reaching value of US$46.6 mn through 2024. Request …

AbbVie

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges … Myers Squibb, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis along with their product portfolio, market share, and other details. The major objective of this Bipolar Forceps and Microscissors Industry report is

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com . Halozyme Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the …

Celgene Corp

Amgen to Buy Celgene’s Otezla: 5 ETF Drugs | Zacks | 8/27/2019

Bristol-Myers Squibb’s ( BMY - Free Report ) proposed acquisition of Celgene Corp ( CELG - Free Report ) for $74 billion in a cash-and-stock deal (read: Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus ).Otezla offers huge growth to Amgen as it has patent exclusivity through at least 2028 in the United States. Additionally, the drug will provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits in …

US Stock Market Overview – Stock Surge as Trump Flip Flops Lifting Dow Industrials | Yahoo News | 8/27/2019

Bristol-Myers Squibb cleared a major hurdle to complete its $74 billion acquisition of Celgene Corp, allowing the stock price to surge. Durable goods orders came in stronger than expected, which helped US yields rise and the dollar to gain traction. President Trump is Generating Volatility President Trump was on the tape on Monday, making comments from the G7 meeting in Europe. The President said that China has reached out …

GlaxoSmithKline

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges … Bristol-Myers Squibb, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis along with their product portfolio, market share, and other details. The major objective of this Bipolar Forceps and Microscissors Industry report

Peptide Therapeutics Market – Growing Involvement of Pharmaceutical Companies to Trigger Market Growth | 9/13/2019

Bristol-Myers Squibb, GlaxoSmithKline plc, Novo Nordisk A/S, and AstraZeneca PLC. Transparency Market Research (TMR) has prepared a report which predicts the market to expand at 9.10% CAGR during the assessment period of 2016 – 2024. The research analysts at TMR prophesize that the global peptide therapeutics market is likely to acquire prominence reaching value of US$46.6 mn through 2024. Request a Sample of Peptide Therapeutics Market Report – https …

Allergan

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb – Market Segment | 9/14/2019

Global Bipolar Forceps and Microscissors Market Key Players 2019 – AstraZeneca, Bristol-Myers Squibb indexmarketsresearch September 14, 2019 Bipolar Forceps and Microscissors The Global Bipolar Forceps and Microscissors Market covering all its essential aspects. This ranges … are analyzed AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis along with their product portfolio, market share, and other details. The major objective of this Bipolar Forceps and

Global Neurology Market Research Overview 2019: Competitive Environment, Regulations, Epidemiology, M&As, Pipeline Drugs | PR Newswire | 9/12/2019

Allergan Plc Apotex, Inc. Astrazeneca Plc Aurobindo Pharma Autism Therapeutics Avanir Pharmaceuticals Inc. Boehringer Ingelheim Bristol-Myers Squibb Co. Biogen Daiichi Sankyo Co., Ltd. Dr. Reddy’S Laboratories Ltd. Eli Lilly And Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ag Glaxosmithkline Plc Gedeon Richter Plc Immunocellular Therapeutics, Ltd. Johnson & Johnson Lannett Co., Inc. H. Lundbeck A/S Lupin Ltd. Mallinckrodt Merck & Co Mylan Nv Nextsource Biotechnology Llc Novartis Ag Otsuka …

Gilead Sciences

Medicine Market Overview, Manufacturing Cost Structure Analysis, Growth Opportunities & Restraints to 2019 – 2023 | 9/12/2019

Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva, Bayer, Novo Nordisk, Allergan, Shire, Boehringer Ingelheim, Takeda. Get Sample Copy of this Report at https://www.reportsweb.com/inquiry&RW00012718245/sample The research report uncovers accurate information about the long run prospects of this Medicine market and reveals the complete study of the industry sectors, business development, and current market. The foremost objective of this report is to send …

Advances in Biotechnology May Offer Cancer Patients … | MarketWatch | 9/10/2019

Gilead Sciences, Inc. GILD, +2.33% , AbbVie Inc. ABBV, -1.36% , Bristol-Myers Squibb Company BMY, -0.37% The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, it was estimated that 1.73 million in the U.S. were affected by cancer in 2018. Additionally, the report also suggested that 609,640 people passed away due to cancer. Overall, cancer research has accelerated over the …

Biogen

Bristol-Myers Squibb Board Announces Election of Three New Directors | Business Wire | 9/12/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected three new independent Directors: Michael Bonney, Dr. Julia A. Haller and Phyllis Yale will join the Board effective … to Cubist, he was Vice President, Sales and Marketing at Biogen, Inc. Prior to joining Biogen, Mr. Bonney spent eleven years at Zeneca Pharmaceuticals, in a range of commercial, operating and strategic roles, ending his

Global Neurology Market Research Overview 2019: Competitive Environment, Regulations, Epidemiology, M&As, Pipeline Drugs | PR Newswire | 9/12/2019

Bristol-Myers Squibb Co. Biogen Daiichi Sankyo Co., Ltd. Dr. Reddy’S Laboratories Ltd. Eli Lilly And Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ag Glaxosmithkline Plc Gedeon Richter Plc Immunocellular Therapeutics, Ltd. Johnson & Johnson Lannett Co., Inc. H. Lundbeck A/S Lupin Ltd. Mallinckrodt Merck & Co Mylan Nv Nextsource Biotechnology Llc Novartis Ag Otsuka Holdings Co., Ltd. Pfizer Inc. Sanofi Sumitomo Dainippon Pharma Co., Ltd. Sun Pharmaceutical Industries Ltd …

Goldman Sachs

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits | Markets Insider | Business Insider | 8/26/2019

… that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla ® (apremilast), the only … LLC is acting as the lead financial advisor to Amgen. Goldman Sachs & Co. is serving as a financial advisor and Sullivan & Cromwell LLP is serving as legal advisor to Amgen. Amgen To Webcast Investor Call …

Morgan Stanley

Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference - Sept. 3, 2019 | 9/3/2019

Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference - Sept. 3, 2019 Sept. 3, 2019 10:59 UTC NEW YORK–( BUSINESS WIRE )– Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York. Giovanni Caforio, M.D. , chairman and chief executive officer will answer questions at 4:15 p.m. ET. Investors and the general public are …

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion | Business Wire | 8/26/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under … into the closing of the pending merger with Celgene. Advisors Morgan Stanley & Co. LLC is serving as financial advisor to Bristol-Myers Squibb, and Kirkland & Ellis LLP is serving as Bristol-Myers Squibb’s legal counsel

Wellington Management

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal - TheStreet.com | 6/24/2019

Bristol-Myers Squibb ( BMY - Get Report ) slumped to the bottom of the S&P 500 Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of … been challenged by key Bristol-Myers shareholders Starboard Value and Wellington Management, ahead of the April vote. Watch: G-20 Summit: Three Things Investors Should Know

Atreca Proposes Terms For $125 Million IPO - Atreca (Pending:BCEL) | Seeking Alpha | 6/14/2019

… 2020. Below is the current status of the company’s drug development pipeline: Source: Company registration statement Investors in Atreca include Wellington Management, Samsara BioCapital, Tavistock Group, Redmile Group, Cormorant Asset Management, Boxer Capital, Aisling Capital … competitors that provide or are developing treatments include: AstraZeneca ( AZN ) Bristol-Myers Squibb ( BMY ) Genentech Merck & Co. ( MRK ) Adaptive Biotechnologies AIMM Therapeutics Neurimmune OncoResponse Vir Biotechnology Source: Sentieo Atreca’s approach relies on identifying unique antibody …

SVB Leerink

Amgen stock pops after company agrees to buy Celgene’s blockbuster anti-inflammatory drug Otezla - MarketWatch | 8/26/2019

SVB Leerink’s Geoffrey Porges wrote in a note to clients Tuesday morning. The psoriasis pill brought in $1.6 billion in sales in 2018, and analysts polled by FactSet expect that number to grow to $1.9 billion in 2020 and $3.1 billion in 2021. Celgene CELG, +3.20% , which is set to merge with Bristol-Myers Squibb Co. BMY, +3.28% , is selling Otezla to allay anti-competitive concerns raised by the U.S …

When it comes to cancer drug deals, one hot protein family is raking in billions: report | FiercePharma | 8/21/2019

… pharma M&A—one that has spawned nearly $100 billion in deals since 2010, according to a new analysis from SVB Leerink. Almost 40% of the total value of pharma deals completed in that timeframe … Roche’s Rozlytrek for lung cancer and myelofibrosis treatment Inrebic from Bristol-Myers Squibb’s newly acquired Celgene. With 23 new kinase inhibitors in phase 3 testing, the fast-growing class of drugs could continue to grab …

Citigroup

Kahn Brothers’ Top 6 Buys in the 2nd Quarter | Yahoo News | 8/7/2019

Reblog Kahn Brothers ( Trades , Portfolio ), founded by legendary investor Irving Kahn, disclosed this week its top six buys for the second quarter were Merck & Co. Inc. (NYSE:MRK), Seaboard Corp. (SEB), Bristol-Myers Squibb Co. (NYSE:BMY), Assured Guaranty Ltd. (NYSE:AGO), GlaxoSmithKline PLC (NYSE:GSK) and Citigroup Inc. (NYSE:C). The New York-based firm follows a contrarian value strategy that branches from Benjamin Graham’s “discounted to net asset …

Don’t Trade, Invest: Cramer’s ‘Mad Money’ Recap (Monday 7/15/19) - TheStreet | 7/16/2019

… your homework. And play it safe. Cramer and the AAP team have the complete rundown for earnings, including banking giants Citigroup ( C - Get Report ) , JP Morgan ( JPM - Get Report ) , and Goldman Sachs ( GS - Get Report … Round, Cramer was bullish on Marvell Technology ( MRVL - Get Report ) , Bristol-Myers Squibb ( BMY - Get Report ) and Eli Lilly ( LLY - Get Report ) . Cramer was bearish on General Motors ( GM - Get Report ) , DuPont ( DD - Get Report …

RBC Capital Markets

Celgene to sell psoriasis drug Otezla for $13.4 billion to Amgen | Yahoo News | 8/26/2019

… said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene. Bristol-Myers … valuing a deal for the drug at about $9 billion. RBC Capital Markets analyst Brian Abrahams, who had earlier said that Otezla was a better fit for Gilead Sciences Inc, also pointed to the high …

Amgen to buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash | Yahoo News | 8/26/2019

… said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene. Bristol-Myers … valuing a deal for the drug at about $9 billion. RBC Capital Markets analyst Brian Abrahams, who had earlier said that Otezla was a better fit for Gilead Sciences Inc, also pointed to the high …

William Blair

Bristol-Myers Squibb Co (NYSE:BMY) to Post Q1 2020 Earnings of $1.22 Per Share, William Blair Forecasts | 9/9/2019

Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at William Blair raised their Q1 2020 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Thursday, September 5th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $1.22 per share for the quarter, up from their prior forecast of $1.18. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2020 …

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/7/2019

… Dyer - Chief of Staff to the Stuart Peltz - Marcio Souza - Chief Operating Officer Emily Hill - Chief Financial Officer Raju Prasad - William Blair Alethia Young - Cantor Fitzgerald Peter Kim - Barclays Martin Auster - Credit Suisse Vincent Chen … that PTC has signed a long-term lease agreement with Bristol-Myers Squibb Company, under which we gain access to approximately 185,000 square feet of space. This includes an existing state-of-the-art biologics …

Merrill Lynch

Denmark’s Genmab files for $500M Nasdaq listing in US | MedCity News | 5/29/2019

… its US market debut, according to the Form F-1. Morgan Stanley is the lead book runner, joined by BofA Merrill Lynch, Guggenheim Securities, Jefferies and RBC Capital Markets. The company’s lead product is Darzalex … Other drug candidates in early development are partnered with Janssen, Bristol-Myers Squibb and others companies, along with about 20 preclinical programs. In its Form F-1, the company said it hopes to launch its …

Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 | Markets Insider | Business Insider | 5/13/2019

… Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer , senior vice president … and biotechnology companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its ENHANZE ® drug delivery technology. Halozyme is headquartered in San Diego . For more information visit www.halozyme.com. Contact: Al …

Biogen Idec

Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board | Globe Newswire | 4/23/2019

Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His extensive drug discovery and development experience in autoimmune and inflammatory diseases and cancer has resulted in multiple drugs entering clinical trials and three registered drugs. He currently serves on the Board of Directors of Amplia Therapeutics, AdAlta and Avalia Immunotherapies and has been a consultant for several other biotechnology companies. Dr. Peach is the co …

KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer | Business Wire | 4/16/2019

Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson & Johnson. Mr. Pagán received his BSE in Chemical Engineering from Princeton University and his MBA from Columbia Business School. “I am extremely pleased to be joining the KSQ team as the company embarks on tremendous growth opportunities to advance medicines that will have a meaningful …

Jefferies Financial Group

Calls of the day: Uber, Lyft, Walmart, Target & more | CNBC | 5/3/2019

Atlantic Equities initiated Uber as neutral Atlantic Equities initiated Lyft as underweight Bernstein upgraded Walmart to outperform from market-perform Bernstein downgraded Target to market-perform from outperform Jefferies upgraded Tilray to hold from underperform Barclays upgraded Bristol-Myers Squibb to overweight from equal-weight RBC upgraded American Express to sector perform from underperform Deutsche Bank upgraded TripAdvisor to buy from hold Goldman Sachs downgraded Cigna to buy from conviction …

As Roundup suits pile on, Bayer’s drugs deliver a surprisingly good show | FiercePharma | 4/25/2019

Apr 25, 2019 12:30pm Lawsuits alleging Bayer’s weedkiller Roundup caused cancer have increased to 13,400. (Bayer) It’s no surprise that blood thinner Xarelto and vision drug Eylea drove Bayer’s pharma growth again this quarter—they have been for a long time. But cancer drugs Nexavar and Stivarga and hemophilia therapy Jivi unexpectedly held firm despite intense competition. Both Nexavar’s and Stivarga’s increases were attributed to a volume jump in China …

HCA

EW Healthcare Partners Raises Over $745 Million Fund 2 | PR Newswire | 8/23/2019

Team of Experienced Healthcare Investors and Former Healthcare Executives Will Invest in Select Healthcare Companies to Seek to Accelerate Their Revenue Growth Partner and Principals Promoted in London , New York and Palo Alto Offices NEW … A/S; Lamberto Andreotti , senior advisor and former Chairman of Bristol-Myers Squibb Company; Tom Caskey , senior advisor and former President of the Merck Genome Research Institute; Bryan Morton , operating partner and former CEO and

EW Healthcare Partners racks up $745 mln for fund | PE Hub | 8/22/2019

EW Healthcare Partners racks up $745 mln for fund August 22, 2019 EW Healthcare Partners has raised $745 million for its second growth equity fund, beating its $650 million target. Fund2a targets healthcare companies in … A/S; Lamberto Andreotti, senior advisor and former Chairman of Bristol-Myers Squibb Company; Tom Caskey, senior advisor and former President of the Merck Genome Research Institute; Bryan Morton, operating partner and former CEO and

Massachusetts General Hospital

Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers | PR Newswire | 8/6/2019

DUBLIN , Aug. 6, The “Neoantigen Targeted Therapies Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. The Neoantigen Targeted Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. One of the key objectives of the …

Biohaven Provides Update On Phase 2/3 Alzheimer’s Disease Clinical Trial: Over 400 Patients Enrolled - NASDAQ.com | 7/22/2019

Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven’s lead development programs include multiple compounds across its CGRP receptor antagonist, glutamate modulation and myeloperoxidase inhibition platforms. More information about Biohaven is available at www.biohavenpharma.com . About ADCS The Alzheimer’s Disease Cooperative Study (ADCS) at the University of California San Diego is an academic research organization that promotes the discovery and testing of …

MD Anderson Cancer Center

CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting | Markets Insider | Business Insider | 6/1/2019

… PROCLAIM-CX-072 Session: Developmental Immunotherapy and Tumor Immunobiology (Poster 157) Presenter: Aung Naing, M.D., FACP, The University of Texas MD Anderson Cancer Center The PROCLAIM-CX-072 monotherapy Part D phase is examining safety … wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com. CytomX Therapeutics Forward-Looking Statements This press release includes forward-looking statements. Such …

Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors | PR Newswire | 5/20/2019

… well-tolerated doses with no dose-limiting toxicities reported of COM701 from the monotherapy dose escalation arm of the trial. Bristol-Myers Squibb will supply Opdivo, a PD-1 inhibitor, for the combination arms of … now has ten participating sites, having recently added Columbia University , MD Anderson Cancer Center, UCLA , the Cleveland Clinic and START Midwest. The primary endpoints for the study are safety and tolerability; secondary endpoints include preliminary …

Harvard Medical School

Bristol-Myers Squibb Board Announces Election of Three New Directors | Business Wire | 9/12/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected three new independent Directors: Michael Bonney, Dr. Julia A. Haller and Phyllis Yale will join the Board effective … graduate of Princeton, Dr. Haller received her M.D. degree from Harvard Medical School. She served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins

Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor | BMJ | 8/19/2019

… epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor 1 Joslin Diabetes Center , Harvard Medical School , Boston , Massachusetts , USA 2 Laboratory for Statistical and Translational Genetics, Center for … Lilly). MH received scholarship donations from three pharmaceutical companies (Astellas, Bristol-Myers Squibb and Eisai). MT received scholarship donations from seven pharmaceutical companies (Pfizer Japan Inc., Astellas, Takeda Pharmaceutical, AbbVie GK Inc., Taisho-Toyama Pharmaceutical …

Memorial Sloan Kettering

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Dunkel 3 , Audra K Miller 6 , 7 , Pranav R Santapuram 8 , David H Abramson 1 , 2 1 Ophthalmic Oncology Service , Memorial Sloan Kettering Cancer Center , New York City , New York , USA 2 Department of Ophthalmology … Apexigen, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Eisai, personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted …

Drs. Joshua Bauml, Wei-Chu Victoria Lai, and Aaron Lisberg receive prestigious LUNGevity 2019 Career Development Awards | PR Newswire | 8/15/2019

… treatment in enhancing the immune response in patients with advanced non-small cell lung cancer. Wei-Chu Victoria Lai , MD, Memorial Sloan Kettering Cancer Center, Overcoming chemoresistance through epigenetic modifications in SCLC . Dr. Lai’s laboratory … Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, the Schmidt Legacy Foundation, and individual donors. About LUNGevity Foundation LUNGevity is the nation’s …

Memorial Sloan Kettering Cancer Center

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Dunkel 3 , Audra K Miller 6 , 7 , Pranav R Santapuram 8 , David H Abramson 1 , 2 1 Ophthalmic Oncology Service , Memorial Sloan Kettering Cancer Center , New York City , New York , USA 2 Department of Ophthalmology … Apexigen, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Eisai, personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted …

Drs. Joshua Bauml, Wei-Chu Victoria Lai, and Aaron Lisberg receive prestigious LUNGevity 2019 Career Development Awards | PR Newswire | 8/15/2019

… treatment in enhancing the immune response in patients with advanced non-small cell lung cancer. Wei-Chu Victoria Lai , MD, Memorial Sloan Kettering Cancer Center, Overcoming chemoresistance through epigenetic modifications in SCLC . Dr. Lai’s laboratory … Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, the Schmidt Legacy Foundation, and individual donors. About LUNGevity Foundation LUNGevity is the nation’s …

AHN

Kahn Brothers’ Top 6 Buys in the 2nd Quarter | Yahoo News | 8/7/2019

Reblog Kahn Brothers ( Trades , Portfolio ), founded by legendary investor Irving Kahn, disclosed this week its top six buys for the second quarter were Merck & Co. Inc. (NYSE:MRK), Seaboard Corp. (SEB), Bristol-Myers Squibb Co. (NYSE:BMY), Assured Guaranty Ltd. (NYSE:AGO), GlaxoSmithKline PLC (NYSE:GSK) and Citigroup Inc. (NYSE:C). The New York-based firm follows a contrarian value strategy that branches from Benjamin Graham’s “discounted to net asset …

Could stem cell transplants make BMS’ checkpoint inhibitors work in resistant lymphoma? | FierceBiotech | 8/2/2019

… effective in multiple cancer types, but not so much in treatment-resistant non-Hodgkin lymphoma (NHL). Now, scientists at the Icahn School of Medicine at Mount Sinai have found a possible way to make immune … ineligible for autologous stem cell transplant. The phase 1/2 uses Bristol-Myers Squibb’s approved immuno-oncology drugs Opdivo and Yervoy and has been enrolling patients since May. Opdivo as a monotherapy previously failed to move …

Cleveland Clinic

Debbie’s Dream Foundation and Cleveland Clinic Florida to Host 1st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast | PR Newswire | 8/30/2019

WESTON, Fla. , Aug. 30, Debbie’s Dream Foundation: Curing Stomach Cancer (DDF), in collaboration with Cleveland Clinic Florida, will host the 1 st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast featuring a panel … is supported in part by DDF sponsors: National Platinum Sponsors Bristol-Myers Squibb and Daiichi Sankyo; National Gold Sponsor Lilly Oncology; National Silver Sponsors Astellas Pharma and Merck; Silver Sponsor Baptist Health; Bronze Sponsor Genentech

NSAIDs May Increase CVD Risk in OA | Medscape | 8/12/2019

… chief academic officer of the Heart and Vascular Institute and Lewis and Patricia Dickey Chair in Cardiovascular Medicine at the Cleveland Clinic, Ohio, said that the study “represents an unreliable source of evidence.” According to … and has received honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and the Medicines Company; has received honoraria for participation in review …

HCA Healthcare

Piper Jaffray Convenes Top Leaders in Healthcare for Annual Heartland Summit | Markets Insider | Business Insider | 6/18/2019

… former Chairman & CEO of Cardinal Health, Inc. Robert Bradway, Chairman & CEO of Amgen, Inc. Giovanni Caforio, M.D., Chairman & CEO of Bristol-Myers Squibb Mark Castaneda, CFO & Treasurer of Tilray, Inc. Jeff Chen, M.D., Executive Director … Alexander Hardy, CEO of Genentech, Inc. Sam Hazen, CEO of HCA Healthcare, Inc. Sami Inkinen, Founder & CEO of Virta Health, Inc. Bret Jorgensen, Chairman & CEO of MDVIP Inc. Dave King, Chairman, CEO & President at Laboratory …

Highest-paid CEOs in 2018: Who made the list from healthcare | Becker’s Hospital Review | 5/28/2019

… some of the nation’s largest for-profit hospital systems: King of Prussia, Pa.-based Universal Health Services, Nashville, Tenn.-based HCA Healthcare and Dallas-based Tenet Healthcare. The full list includes 200 chief executives from … R. Milton Johnson — $20 million Pfizer, Ian Read — $20 million Bristol-Myers Squibb, Giovanni Caforio — $19 million Cigna, David Cordani — $19 million Vertex Pharmaceuticals, Jeffrey Leiden — $19 million Thermo Fisher Scientific, Marc Casper — $19 million …

Cleveland Clinic, Cleveland OH

Debbie’s Dream Foundation and Cleveland Clinic Florida to Host 1st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast | PR Newswire | 8/30/2019

WESTON, Fla. , Aug. 30, Debbie’s Dream Foundation: Curing Stomach Cancer (DDF), in collaboration with Cleveland Clinic Florida, will host the 1 st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast featuring a panel of leading oncologists and healthcare experts from around the world. The event will take place on Saturday, November 9, 2019 , from 8 a.m. to 5 p.m. at Cleveland Clinic in Weston, Florida , and will be …

NSAIDs May Increase CVD Risk in OA | Medscape | 8/12/2019

NSAIDs May Increase CVD Risk in OA Janis C. Kelly August 12, 2019 In the first study to examine the possible role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the elevated risk for cardiovascular disease (CVD) of patients with osteoarthritis (OA), it was estimated that NSAIDS might account for 41% of the association between OA and CVD. This, the authors indicate, has huge public health implications, because more than three …

Cigna

Cna Financial Corp Buys Cheniere Energy Inc, Bristol-Myers Squibb Company, Cigna Corp, Sells … | 8/22/2019

… portfolio. Shares added by 1.83% Kinder Morgan Inc ( KMI ) - 500,000 shares, 2.21% of the total portfolio. Shares added by 10.86% Cigna Corp ( CI ) - 65,500 shares, 2.19% of the total portfolio. Shares added by 84.51% New … 1.09%. The holding were 75,000 shares as of . New Purchase: Bristol-Myers Squibb Company ( BMY ) Cna Financial Corp initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $44.62 and $49.34, with an …

9 Stocks Top Managers Are Buying | Morningstar | 8/14/2019

… as of this writing, trading at 3-star levels. The Dodge & Cox team has also added to its stake in Cigna ( CI ) . They expect Cigna to achieve significant cost savings from its pickup of Express … this writing. Dodge & Cox’s managers bulked up their position in Bristol-Myers Squibb ( BMY ) , which is acquiring Celgene ( CELG ) . “The combined company will have nine products with more than $1 billion in annual sales and …

Aetna

Precision healthcare startup GNS lands $23M from Cigna Ventures | MobiHealthNews | 7/9/2019

… Ventures, Celegene, Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, the former CEO of Caesar and division president of Aetna. WHAT THEY DO The company’s platform, dubbed REFS (Reverse Engineering and Forward Simulation), is … boast a list of pharma clients that includes Johnson & Johnson, Bristol-Myers Squibb and Novartis. GNS has gone through funding rounds before. In fact, this new announcement comes roughly four years after GNS Healthcare landed …

These 3 High-Yield Blue Chips Are Very Strong Buys - Bristol-Myers Squibb Company (NYSE:BMY) | Seeking Alpha | 5/16/2019

… in the Bristol section) but the largest reason shares have crashed is concerns over the $78 billion mega acquisition of Aetna (which the company possibly overpaid for to the tune of about $20 billion ), the … trading at high margins of safety and ridiculously attractive valuations. Bristol-Myers Squibb: Celgene Merger Creates Large Opportunities For Long-Term Profit Bristol’s shares have been badly hurt not just due to overall fears over …

Humana

Trading CVS Stock After Big Pop on White House News - TheStreet | 7/11/2019

Humana ( HUM ) is up 3.7% and Centene ( CNC ) climbed 3.5%. However, Walgreens ( WBA ) is flat on the day. On the flip side, drugmakers are under pressure, with Bristol-Myers Squibb ( BMY ) , Gilead Sciences ( GILD ) , Biogen ( BIIB ) , Regeneron ( REGN ) and others all under pressure. For CVS Health, though, the rally sparked a potentially large move in the name. In many investors’ eyes, the stock has been unfairly punished, falling throughout most …

Healthcare stocks under pressure ahead of Dem debate - AmerisourceBergen Corporation (NYSE:ABC) | Seeking Alpha | 6/26/2019

… Health Care Select Sector SPDR ETF ( XLV -1.2% ), Vanguard Health Care ETF ( VHT -1.3% ), Abbott ( ABT -1.3% ), AstraZeneca ( AZN -1.3% ), Bristol-Myers Squibb ( BMY -0.8% ), GlaxoSmithKline ( GSK -1% ), Johnson & Johnson ( JNJ -2% ), Eli Lilly ( LLY … AmerisourceBergen ( ABC -0.6% ), Tenet Healthcare ( THC -1.8% ), HCA ( HCA -1.5% ), Humana ( HUM -0.2% ) See all stocks on the move » Now read: Bristol-Myers Squibb: Share Repurchases No Benefit To Shareholders …

Anthem

RXL, BMY, CVS, ANTM: ETF Outflow Alert - Nasdaq.com | 4/25/2019

Bristol-Myers Squibb Co. (Symbol: BMY) is up about 0.9%, CVS Health Corporation (Symbol: CVS) is up about 0.1%, and Anthem Inc (Symbol: ANTM) is up by about 0.4%. For a complete list of holdings, visit the RXL Holdings page » The chart below shows the one year price performance of RXL, versus its 200 day moving average: Looking at the chart above, RXL’s low point in its 52 week range …

AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect - MarketWatch | 4/24/2019

Health-care earnings announcements are in full swing. Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc. , Biogen Inc. , Boston Scientific Corp. and Swiss drugmaker Novartis AG reported on Wednesday. Next up are AbbVie Inc. ABBV, +0.85% and Bristol-Myers Squibb Co. BMY, +2.29% Here’s what investors can expect on Thursday as these two pharmaceutical giants report first-quarter earnings. AbbVie, which is expected to report earnings …

UnitedHealthcare

CVS, Cigna, Humana at Senate hearing blame Big Pharma for high drug prices | CNBC | 5/13/2019

… patients pay for medication, pointing the finger at Big Pharma instead. The companies — CVS Health , Cigna , Prime Therapeutics, Humana and UnitedHealthcare ‘s OptumRx — said rebates paid by drug companies to PBMs, sometimes called “middlemen,” are … the committee heard testimony from drug executives of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi. The pharma executives at the time didn’t talk much about list prices. Instead, they blamed middlemen …

Brainstorm Health: Bristol-Myers Drug, Brain Implant, UnitedHealth Maternity Cost Program | Fortune | 5/10/2019

… government) are already experimenting with certain strategies that are a common feature of universal health care plans—including insurance giant UnitedHealthcare. On Thursday, the company announced a new “bundled payment” program for maternal medical services … to brain cancer treatments as Bristol-Myers drug fails study. Bristol-Myers Squibb’s flagship cancer immunotherapy drug Opdivo failed a late-stage trial in a form of advanced brain cancer (glioblastoma). It’s not necessarily a …

Centene Corp

Merger Arbitrage Mondays - Cypress Semiconductor Deal Speculation Confirmed | Seeking Alpha | 6/4/2019

… Financial, Inc. ( FNF ) $49.77 $41.13 06/30/2019 21.00% 283.92% PACB 11/01/2018 Illumina, Inc. ( ILMN ) $8.00 $6.7 06/30/2019 19.40% 262.30% WCG 03/27/2019 Centene Corporation ( CNC ) $315.20 $276.19 06/30/2020 14.12% 13.12% MLNX 03/11/2019 NVIDIA Corporation ( NVDA ) $125.00 $109.78 … I hold long positions in Red Hat (RHT), Celgene (CELG), Bristol-Myers Squibb (BMY) and Finisar (FNSR). Please do your own due diligence before buying or selling any securities mentioned in this article. We do …

AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect - MarketWatch | 4/24/2019

Health-care earnings announcements are in full swing. Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc. , Biogen Inc. , Boston Scientific Corp. and Swiss drugmaker Novartis AG reported on Wednesday. Next up are AbbVie Inc. ABBV, +0.85% and Bristol-Myers Squibb Co. BMY, +2.29% Here’s what investors can expect on Thursday as these two pharmaceutical giants report first-quarter earnings. AbbVie, which is expected to report earnings …

Giovanni Caforio

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion | Business Wire | 8/26/2019

NEW YORK- Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under … for patients with psoriasis, psoriatic arthritis and Behçet’s Disease,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with the OTEZLA team, Amgen has the capabilities and infrastructure to continue

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion | Business & Finance | heraldchronicle.com | Business Wire | 8/26/2019

NEW YORK–(BUSINESS WIRE)–Aug 26, 2019– Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement … for patients with psoriasis, psoriatic arthritis and Behçet’s Disease,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with the OTEZLA team, Amgen has the capabilities and infrastructure to continue

Vlad Coric

Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments | PR Newswire | 8/9/2019

… reported financial results for the quarter ended June 30, 2019 , and provided a review of recent accomplishments and anticipated milestones. Vlad Coric , M.D., CEO of Biohaven commented, “The submission of our NDAs to the FDA … formulations of rimegepant; accrual for CGRP development milestones payable to Bristol-Myers Squibb Company in the amount of $11.5 million ; one-time issuance of common shares to Fox Chase Chemical Diversity Center Inc. which resulted …

Vamil Divan

Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements | FiercePharma | 8/2/2019

With Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million could help soothe BMS’ mind … core assets in the merger, according to Credit Suisse analyst Vamil Divan, but it would have delivered some significant cash flow to the combined company’s top line, and not every analyst agreed. RELATED: Among recent

Could FTC scrutiny of the Roche-Spark merger scuttle future pharma deals? Analysts are fretting | FiercePharma | 8/2/2019

… Yee in a note to clients. The FTC’s monopoly fears have already dampened one big merger this year. In June, Bristol-Myers Squibb said that as part of its $74 billion merger with Celgene, it … with its own IL-23 inhibitor, brazikumab, Credit Suisse analyst Vamil Divan pointed out in a recent note to investors. RELATED: Who’s the next Big Pharma takeout target? Biogen, uniQure, AZ top the list: report …

Fouad Namouni

European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire | 8/27/2019

PRINCETON, N.J.- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and … treatment is a heavy burden for patients to carry,” said Fouad Namouni, M.D., head, Oncology Development, Bristol-Myers Squibb. “We are proud that the European Commission has again recognized the role of Empliciti in helping

European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma – Company Announcement - FT.com | Financial Times | 8/27/2019

… dose dexamethasone alone Second Empliciti- based combination approved in Europe for patients with relapsed and refractory multiple myeloma PRINCETON, N.J. Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved … treatment is a heavy burden for patients to carry,” said Fouad Namouni, M.D., head, Oncology Development , Bristol-Myers Squibb . “We are proud that the European Commission has again recognized the role of Empliciti in helping …

Johanna Mercier

Chutes & Ladders—Gilead CEO continues top-level revamp with 3 more exec exits | FierceBiotech | 7/19/2019

Bristol-Myers Squibb’s Johanna Mercier as commercial chief, displacing Laura Hamill after less than a year, and more recently brought on Eli Lilly’s Christi Shaw for the newly created CEO post at its Kite Pharma subsidiary. But O’Day still has more shoes to fill: In April, longtime CFO Robin Washington said she would retire next year. FierceBiotech FiercePharma Case Study [Case Study] Clinical Supply Management Download this case study to …

Richard Gonzalez

Protect at All Costs: How the Maker of the World’s Bestselling Drug Keeps Prices Sky-High | Fortune | 7/18/2019

… applied for and won 75 Humira patents in the three years before its initial patent expired in 2016. AbbVie CEO Richard Gonzalez has said the company now holds approximately 136 Humira patents. How was the … Jenkins led major R&D divisions at drug giants like Bristol-Myers Squibb and Germany’s Merck Serono as they pumped out pioneering new treatments such as the cancer immunotherapy Yervoy, among others, in the 1990s …

Pharma’s top jet-setting executives of 2018 | FiercePharma | 7/18/2019

… rankings. Despite criticism from some market watchers, the company said it plans to continue honoring the setup in 2019. 2. Richard Gonzalez, AbbVie chairman and CEO, $598,447 AbbVie’s Richard Gonzalez may have been the executive … 213,287 in moving and relocation costs in 2018 after leaving Bristol-Myers Squibb, including a $94,283 in tax gross-ups. Brent Saunders 10. Brent Saunders, Allergan chairman and CEO, $80,946 Allergan and Brent Saunders both …

Rupert Vessey

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 7/26/2019

Bristol-Myers Squibb Company (NYSE: BMY ) Q2 2019 Results 25, 2019 11:00 John Elicker - SVP, Public Affairs and IR Giovanni Caforio - Chairman and CEO Charlie Bancroft - CFO Chris Boerner - Chief Commercial Officer Fouad Namouni - Head … priority for the combined company, we’ve named two talented leaders, Rupert Vessey and Samit Hirawat to run the research and late stage development organizations, respectively. I’m pleased to note that Samit has been with BMS

Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript - Nasdaq.com | 7/26/2019

Image source: The Motley Fool. Co (NYSE: BMY) Q2 2019 Earnings Call Jul 25, 2019 , 10:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, and welcome to the 2019 Second Quarter Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Mr. John Elicker, Senior Vice President, Public Affairs and Investor Relations. Please …

Charlie Bancroft

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 7/26/2019

Bristol-Myers Squibb Company (NYSE: BMY ) Q2 2019 Results 25, 2019 11:00 John Elicker - SVP, Public Affairs and IR Giovanni Caforio - Chairman and CEO Charlie Bancroft - CFO Chris Boerner - Chief Commercial Officer Fouad Namouni - Head, Oncology Development Tim Anderson - Wolfe research Seamus Fernandez - Guggenheim Chris Schott - JP Morgan Navin Jacob - UBS Terence Flynn - Goldman Sachs Steve Scala - Cowen Matt Phipps - William Blair Jason Gerberry - Bank of America Umer Raffat - Evercore …

Chutes & Ladders—Bristol-Myers unveils post-Celgene R&D team | FierceBiotech | 6/7/2019

… it here at the end of each week. Bristol-Myers unveils team to lead R&D after Celgene deal closes Bristol-Myers Squibb BMS Chief Scientific Officer Tom Lynch is set to leave by the … the industry. Meanwhile, Celgene CFO David Elkins will replace BMS’ Charlie Bancroft , who will focus on integration until he retires next year. On the commercial side, Celgene’s hematology and oncology chief Nadim Ahmed will head …

Tom Lynch

Amid BMS R&D shuffle, F-star nabs its immuno-oncology executive | FierceMedicalDevices | 6/10/2019

by Ben Adams Jun 10, 2019 9:30am Bristol-Myers Squibb once had an option to buyout F-star but opted against it back in 2017. (Bristol-Myers Squibb) Last week, Bristol-Myers Squibb announced it … amid a big shuffle, with Bristol-Myers’ Chief Scientific Officer Tom Lynch, who has been involved in the areas covered by research and early development for two years, is also set to leave the biopharma

Amid BMS R&D shuffle, F-star nabs its immuno-oncology executive | FierceBiotech | 6/10/2019

by Ben Adams Jun 10, 2019 9:30am Bristol-Myers Squibb once had an option to buyout F-star but opted against it back in 2017. (Bristol-Myers Squibb) Last week, Bristol-Myers Squibb announced it … amid a big shuffle, with Bristol-Myers’ Chief Scientific Officer Tom Lynch, who has been involved in the areas covered by research and early development for two years, is also set to leave the biopharma

Helen Torley

Halozyme To Participate In 2019 Wells Fargo Healthcare Conference | Business & Finance | heraldchronicle.com | PR Newswire | 8/26/2019

… developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo Healthcare Conference in Boston, MA. Dr. Helen Torley, president and chief executive officer, will provide an overview of the company on … and biotechnology companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com . Contact: Al …

Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript - Nasdaq.com | 8/8/2019

… will be referenced on today’s call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme’s President and Chief Executive Officer, who will provide an update on our … products in Phase 1 development by our partners Argenx, Alexion, Bristol-Myers Squibb, Lilly and Roche. We were pleased to announce last month that Argenx had dealt with the first patient in a Phase 1 …